Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 503)

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGE IN

COMPOSITION OF REMUNERATION COMMITTEE, AUDIT

COMMITTEE AND EXECUTIVE COMMITTEE

The board of directors (the "Board") of Lansen Pharmaceutical Holdings Limited (the "Company") hereby announces that Mr. Lee Jin Yi ("Mr. Lee") has resigned as a Non-executive Director of the Company as well as a member of the Remuneration Committee, a member of Audit Committee and the deputy chairman of the Executive Committee with effect from 31 October 2019 due to his retirement.

Mr. Lee has been a director of the Company since April 2010. He has provided valuable advice and support to the Company during his tenure of office. After serving the Company for years, Mr. Lee would like to retire to pursue his personal interests.

Mr. Lee has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Chairman and the Board express their sincere gratitude to Mr. Lee for his service and valuable contribution made to the Company.

By Order of the Board

Lansen Pharmaceutical Holdings Limited

Wu Zhen Tao

Chairman

Hong Kong, 31 October 2019

As

at the

date of

this announcement, the executive managing Director is

Mr.

Chen

Li; the

non-executive Directors are Mr. Wu Zhen Tao, Mr. Stephen Burnau

Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Fritz Heinrich Horlacher and Mr. Yeung Tak Bun, Allen.

Attachments

  • Original document
  • Permalink

Disclaimer

Lansen Pharmaceutical Holdings Co. Ltd. published this content on 31 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 October 2019 08:51:01 UTC